Effectiveness and Safety of Lemborexant Over 12 Months in Adults with Insomnia Disorder: Longterm Results From the Phase 3 SUNRISE-2 Study

被引：0

作者：

Yardley, Jane ^{[1
]}

Karppa, Mikko ^{[2
,3
]}

Inoue, Yuichi ^{[4
]}

Pinner, Kate ^{[1
]}

Perdomo, Carlos ^{[5
]}

Filippov, Gleb ^{[5
]}

Kubota, Naoki ^{[6
]}

Moline, Margaret ^{[5
]}

机构：

[1] Eisai Ltd, Bunkyo City, Japan

[2] Oulu Univ Hosp, Oulu, Finland

[3] Univ Oulu, Oulu, Finland

[4] Tokyo Med Univ, Tokyo, Japan

[5] Eisai Inc, Bunkyo City, Japan

[6] Eisai & Co Ltd, Bunkyo City, Japan

来源：

NEUROLOGY | 2020年 / 94卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

420

引用

页数：3

共 50 条

[41] Lanadelumab in Patients 2 to Less Than 12 Years Old With Hereditary Angioedema: Results From the Phase 3 SPRING Study
Maurer, Marcus
Lumry, William R.
Li, H. Henry
Aygoren-Pursun, Emel
Busse, Paula J.
Jacobs, Joshua
Nurse, Christina
Ahmed, Mariam A.
Watt, Maureen
Yu, Ming
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2024, 12 (01): : 201 - 211.e6
[42] Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials (vol 21, pg 125, 2022)
Mignot, E.
Mayleben, D.
Fietzeet, I
[J]. LANCET NEUROLOGY, 2022, 21 (03):
[43] Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials (vol 21, pg 125, 2022)
Mignot, E.
Mayleben, D.
Fietze, I
[J]. LANCET NEUROLOGY, 2022, 21 (06): : E6 - E6
[44] SAGE-217 in subjects with major depressive disorder: efficacy and safety results from open-label Part A of a phase 2A study
Gunduz-Bruce, H.
Riesenberg, R.
Sankoh, A.
Li, H.
Nomikos, G.
Doherty, J.
Kaul, I.
Arnold, R.
Miller, P.
Kanes, S.
[J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S856 - S857
[45] Efficacy and Safety of Dextroamphetamine Transdermal System for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Results from a Pivotal Phase 2 Study
Cutler, Andrew J.
Suzuki, Katsumi
Starling, Brittney
Balakrishnan, Kanan
Komaroff, Marina
Castelli, Mariacristina
Meeves, Suzanne
Childress, Ann C.
[J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2022, 32 (02) : 89 - 97
[46] Zuranolone in Major Depressive Disorder: Safety and Tolerability Results From the Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Waterfall Study
Lasser, Robert
Clayton, Anita
Jung, JungAh
Brown, Colville
Kanes, Stephen J.
Doherty, James
[J]. NEUROPSYCHOPHARMACOLOGY, 2021, 46 (SUPPL 1) : 189 - 189
[47] Safety of diazepam nasal spray (Valtoco®) in patients with epilepsy: Final results from a phase 3, open-label, 12-month, repeat-dose safety study
Wheless, James
Sperling, Michael
Liow, Kore
Segal, Eric
Hogan, Robert
Tarquinio, Daniel
Mauney, Weldon
Desai, Jay
Dlugos, Dennis
Biton, Victor
Cascino, Gregory
Carrazana, Enrique
Rabinowicz, Adrian
[J]. EPILEPSIA, 2021, 62 : 146 - 147
[48] Safety Profile of Valtoco® (diazepam nasal spray) in Patients With Epilepsy: Final Results From a Phase 3, Open-Label, 12-Month Repeat Dose Safety Study
Wheless, James
Sperling, Michael
Liow, Kore
Segal, Eric
Miller, Ian
Hogan, R. Edward
Tarquinio, Daniel
Desai, Jay
Dlugos, Dennis
Biton, Victor
Cascino, Gregory
Carrazana, Enrique
Rabinowicz, Adrian L.
[J]. NEUROLOGY, 2021, 96 (15)
[49] EFFICACY, SAFETY, AND TOLERABILITY OF ORALLY ADMINISTERED ATOGEPANT FOR THE PREVENTION OF EPISODIC MIGRAINE: RESULTS FROM A PHASE 2B/3 STUDY
Goadsby, P. J.
Dodick, D. W.
Trugman, J. M.
Finnegan, M.
Lakkis, H.
Lu, K.
Szegedi, A.
[J]. CEPHALALGIA, 2018, 38 : 144 - 145
[50] Safety and Efficacy of Upadacitinib for Atopic Dermatitis in Japan: 2-Year Interim Results from the Phase 3 Rising Up Study
Norito Katoh
Yukihiro Ohya
Hiroyuki Murota
Masanori Ikeda
Xiaofei Hu
Kimitoshi Ikeda
John Liu
Takuya Sasaki
Eliza M. Raymundo
Henrique D. Teixeira
Hidehisa Saeki
[J]. Dermatology and Therapy, 2023, 13 : 221 - 234

← 1 2 3 4 5 →